GHCM
HRTX icon

Glen Harbor Capital Management’s Heron Therapeutics HRTX Stock Holding History

Glen Harbor Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$17K Hold
946
– – ﹤0.01% 1306
2019
Q2 		$18K Buy
+946
New +$18.9K ﹤0.01% 1302

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Glen Harbor Capital Management's HRTX Position: Q3 2019 in Review

Glen Harbor Capital Management held its Heron Therapeutics (HRTX) position steady in Q3 2019 at 946 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

Glen Harbor Capital Management first reported a position in HRTX in Q2 2019 and has held it in 2 quarters since. The position peaked at $18K in Q2 2019. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

  • Glen Harbor Capital Management held 946 shares of Heron Therapeutics worth $17K as of Q3 2019.
  • Glen Harbor Capital Management left its Heron Therapeutics share count unchanged in Q3 2019.
  • Heron Therapeutics made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1306 holding.
  • Glen Harbor Capital Management first reported a position in Heron Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • Glen Harbor Capital Management's Heron Therapeutics position peaked at $18K in Q2 2019.
  • 180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.